Products Rotarix + RotaTeq
Rotarix + RotaTeq Phase 3 Completed ⚡ Active Interest: 40/100
Nov 1, 2013 → Nov 1, 2017
About Rotarix + RotaTeq Rotarix + RotaTeq is a phase 3 stage product being developed by Merck for Rotavirus Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT02193061. Target conditions include Rotavirus Vaccine.
What happened to similar drugs? 1 of 12 similar drugs in Rotavirus Vaccine were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02193061 Phase 3 Completed Nov 1, 2013 Nov 1, 2017 Rotavirus Vaccine
Product Company Stage Hype Score Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™ Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered) Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 Rotateq™ + Comparator: Placebo Merck Phase 3 RotaTeq™ (V260) + DTP-IPV Merck Approved Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 rotavirus vaccine, live, oral, pentavalent + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa Merck Phase 3 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) Merck Phase 3